- The companies signed a license agreement to deploy TcBuster for the manufacturing of gene-modified cell therapies
- Luminary gets a non-exclusive license for TcBuster and will use it in the LMY-920 program. Luminary plans to file an IND with the FDA in late 2021
- The license agreement will allow Bio-Techne to increase its presence in the cell and gene therapy market
Click here to read full press release/ article | Ref: PRNewswire | Image: Owler
The post Bio-Techne Collaborates with Luminary to Utilize TcBuster in the Development of CAR-T cell Therapies first appeared on PharmaShots.